Viewing Study NCT01423058


Ignite Creation Date: 2025-12-25 @ 12:03 AM
Ignite Modification Date: 2026-05-23 @ 3:48 AM
Study NCT ID: NCT01423058
Status: COMPLETED
Last Update Posted: 2019-02-04
First Post: 2011-07-07
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
Sponsor: Sierra Oncology LLC - a GSK company
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Myelofibrosis View
None Post-Polycythemia Vera View
None Post-Essential Thrombocythemia Myelofibrosis View
Keywords: